Investigating how maternal exercise and PFAS exposure affect children's development.
Official title: Perinatal PFAS Impact Children's Development: Examining the Roles of Placental Functional Multiomics and Protection by Maternal Exercise
Funded at Arkansas Children's Hospital Res Inst · NIH-11025561 · Data updated 2026-11-12
This study is looking at how being exposed to certain chemicals during pregnancy might affect your child's growth and development, especially in their early years, and it will also explore if staying active while pregnant can help lessen any negative effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arkansas Children's Hospital Res Inst NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $695,853 |
| NIH project number | 1R01ES036986-01 |
| Project ID | NIH-11025561 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include pregnant women and their children, particularly those exposed to PFAS or interested in the effects of maternal exercise on child development.
✕Less likely to help
Patients who are not pregnant or whose children are beyond the early developmental stages may not benefit from this research.
What this research studies
This research focuses on understanding how exposure to per- and polyfluoroalkyl substances (PFAS) during pregnancy can impact the development of children, particularly in their early years. The study examines the role of placental function and how maternal exercise may mitigate some of the adverse effects of PFAS exposure. By analyzing biological samples and developmental outcomes, the research aims to uncover the mechanisms linking prenatal PFAS exposure to health issues in children, including cognitive and language development. The research will involve tracking the health and development of children from birth through early childhood.
Why it matters
Potential benefit: If successful, this research could lead to improved guidelines for maternal health and child development, potentially reducing the negative impacts of environmental toxins.
How similar studies have gone: While there is limited literature on the specific impacts of PFAS on child development, preliminary data suggest that similar approaches have shown promising results in understanding environmental exposures.
Where this research is happening
-
Arkansas Children's Hospital Res Inst
Little Rock, United States Active
Researchers
- Principal investigator: Andres, Aline — Arkansas Children's Hospital Res Inst
- Study coordinator: Andres, Aline
Related research
Other NIH-funded projects on the same topics.
-
Shorter antifungal treatment for kids with candidemia
A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.
-
Short Course vs Standard Course Antifungal Therapy for Pediatric Candidemia
This study tests whether a shorter 7-day total antifungal treatment after an initial 7 days of echinocandin therapy is as effective as the usual 14-day course for children with candidemia.
-
Shorter antifungal treatment for kids with candidemia
A multi-center study tests whether kids with candidemia can finish treatment earlier after an initial week of antifungal therapy than the standard two weeks total.
-
Shorter antifungal treatment for kids with candidemia
This study tests whether children with candidemia can finish treatment after 7 days of an echinocandin if they are improving, instead of completing a full 14 days.
-
Shorter antifungal course for kids with candidemia
A multi-center study tests whether 7 extra days of antifungal therapy after an initial week of treatment can be shortened safely for children with candidemia.
-
Shortened antifungal treatment for kids with candidemia
A pediatric multicenter trial will test whether stopping antifungal therapy after 7 more days, following an initial 7 days of treatment, isas safe as continuing for 14 days.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.